Cargando…
Host-Directed Therapies for Tuberculosis
Tuberculosis (TB) is one of the leading causes of death worldwide, consistently threatening public health. Conventional tuberculosis treatment requires a long-term treatment regimen and is associated with side effects. The efficacy of antitubercular drugs has decreased with the emergence of drug-res...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697779/ https://www.ncbi.nlm.nih.gov/pubmed/36365041 http://dx.doi.org/10.3390/pathogens11111291 |
_version_ | 1784838652705112064 |
---|---|
author | Jeong, Eui-Kwon Lee, Hyo-Ji Jung, Yu-Jin |
author_facet | Jeong, Eui-Kwon Lee, Hyo-Ji Jung, Yu-Jin |
author_sort | Jeong, Eui-Kwon |
collection | PubMed |
description | Tuberculosis (TB) is one of the leading causes of death worldwide, consistently threatening public health. Conventional tuberculosis treatment requires a long-term treatment regimen and is associated with side effects. The efficacy of antitubercular drugs has decreased with the emergence of drug-resistant TB; therefore, the development of new TB treatment strategies is urgently needed. In this context, we present host-directed therapy (HDT) as an alternative to current tuberculosis therapy. Unlike antitubercular drugs that directly target Mycobacterium tuberculosis (Mtb), the causative agent of TB, HDT is an approach for treating TB that appropriately modulates host immune responses. HDT primarily aims to enhance the antimicrobial activity of the host in order to control Mtb infection and attenuate excessive inflammation in order to minimize tissue damage. Recently, research based on the repositioning of drugs for use in HDT has been in progress. Based on the overall immune responses against Mtb infection and the immune-evasion mechanisms of Mtb, this review examines the repositioned drugs available for HDT and their mechanisms of action. |
format | Online Article Text |
id | pubmed-9697779 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96977792022-11-26 Host-Directed Therapies for Tuberculosis Jeong, Eui-Kwon Lee, Hyo-Ji Jung, Yu-Jin Pathogens Review Tuberculosis (TB) is one of the leading causes of death worldwide, consistently threatening public health. Conventional tuberculosis treatment requires a long-term treatment regimen and is associated with side effects. The efficacy of antitubercular drugs has decreased with the emergence of drug-resistant TB; therefore, the development of new TB treatment strategies is urgently needed. In this context, we present host-directed therapy (HDT) as an alternative to current tuberculosis therapy. Unlike antitubercular drugs that directly target Mycobacterium tuberculosis (Mtb), the causative agent of TB, HDT is an approach for treating TB that appropriately modulates host immune responses. HDT primarily aims to enhance the antimicrobial activity of the host in order to control Mtb infection and attenuate excessive inflammation in order to minimize tissue damage. Recently, research based on the repositioning of drugs for use in HDT has been in progress. Based on the overall immune responses against Mtb infection and the immune-evasion mechanisms of Mtb, this review examines the repositioned drugs available for HDT and their mechanisms of action. MDPI 2022-11-03 /pmc/articles/PMC9697779/ /pubmed/36365041 http://dx.doi.org/10.3390/pathogens11111291 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Jeong, Eui-Kwon Lee, Hyo-Ji Jung, Yu-Jin Host-Directed Therapies for Tuberculosis |
title | Host-Directed Therapies for Tuberculosis |
title_full | Host-Directed Therapies for Tuberculosis |
title_fullStr | Host-Directed Therapies for Tuberculosis |
title_full_unstemmed | Host-Directed Therapies for Tuberculosis |
title_short | Host-Directed Therapies for Tuberculosis |
title_sort | host-directed therapies for tuberculosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697779/ https://www.ncbi.nlm.nih.gov/pubmed/36365041 http://dx.doi.org/10.3390/pathogens11111291 |
work_keys_str_mv | AT jeongeuikwon hostdirectedtherapiesfortuberculosis AT leehyoji hostdirectedtherapiesfortuberculosis AT jungyujin hostdirectedtherapiesfortuberculosis |